Every Form 4 that BEONE MEDICINES LTD (BEIGF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BEIGF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEIGF filings page.
BeOne Medicines Ltd. (ONC) director and Scientific Advisory Board chair Wang Xiaodong reported multiple equity transactions on September 8, 2026. He exercised options covering 403,351 Ordinary Shares at an exercise price of $2.84 per share, leaving options on 1,210,079 Ordinary Shares outstanding. On the same date, he acquired 31,027 American Depositary Shares (ADS) (each ADS representing 13 Ordinary Shares) through an exercise or conversion and sold a total of 38,287 ADS in a series of open-market transactions at weighted-average prices in the mid-$300s per ADS, executed under a Rule 10b5-1 trading plan adopted on June 9, 2026. Following these transactions, he directly held 4,588,113 Ordinary Shares and also had indirect interests through family-related entities and a family trust, for which he disclaims beneficial ownership.
BeOne Medicines Ltd. (ONC) reported that Principal Accounting Officer Titus B. Ball sold 132 American Depositary Shares on September 1, 2026 at $355.86 per ADS. The sale was effected pursuant to a mandatory tax withholding provision tied to the vesting of a restricted share unit award. Each ADS represents 13 Ordinary Shares, and following this transaction he directly holds 97,929 Ordinary Shares. No Rule 10b5-1 trading plan is reported.
BeOne Medicines Ltd. (ONC) officer Wu Xiaobin, President and COO, reported selling 280 American Depositary Shares (ADS) of BeOne Medicines on 2026-08-25 at $380.00 per ADS in an open-market or private transaction. Each ADS represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 2025-11-07. After these transactions, Wu reported direct ownership of 1,270,084 Ordinary Shares and indirect ownership of 4,000 ADS held by his wife.
BeOne Medicines Ltd. executive Lee Chan Henry, SVP and General Counsel, reported multiple option exercises and ADS trades on August 11, 2026. He exercised three option grants covering a total of 34,658 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per Ordinary Share. In related non-derivative transactions, he acquired blocks of 812, 1,058, and 796 American Depositary Shares (each ADS representing 13 Ordinary Shares), and sold 2,666 ADS at $360.00 per ADS pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. Following these transactions, he directly held 325,312 Ordinary Shares.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported open-market sales of a total of 240,810 American Depositary Shares (ADS) of the company over August 10–12, 2026, in 24 separate transactions at per-share prices generally between $350 and $367. Each ADS represents 13 Ordinary Shares. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Oyler on March 10, 2026. A direct holding line shows 1,330,988 Ordinary Shares held, and additional Ordinary Shares are held indirectly through various trusts and an IRA, some of which Oyler disclaims beneficial ownership of.
BeOne Medicines Ltd. Chief Financial Officer Aaron Rosenberg sold 1,157 American Depositary Shares at $312.715 per ADS on August 3, 2026, to satisfy mandatory tax withholding tied to vesting of a restricted share unit award. After this transaction he held 382,850 Ordinary Shares directly. Each American Depositary Share represents 13 Ordinary Shares, and the restricted share unit award vests in four equal annual installments on each anniversary of July 31, 2024, with remaining unvested units eligible for accelerated vesting upon certain termination events.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry reported a sale of 1,044 American Depositary Shares on July 30, 2026 at $323.69 per ADS. The sale was executed under a mandatory tax-withholding provision tied to vesting of a restricted share unit award. Each ADS represents 13 ordinary shares, and following the transaction he directly holds 325,312 ordinary shares. The RSU award vests 1/4 of the securities on each anniversary of July 29, 2022, subject to continued service.
BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry exercised options for 21,697 ordinary shares on July 22, 2026, at exercise prices of $14.96, $16.41 and $12.23 per share. He acquired American Depositary Shares at prices of $194.47, $213.32 and $159.03 per ADS, and sold 1,669 ADS at $325 pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. After these transactions he held 338,884 ordinary shares directly.
BeOne Medicines Ltd. director and Chief Executive Officer John Oyler exercised share options covering 441,870 Ordinary Shares at an exercise price of $9.23 per share and on the same date acquired 33,990 American Depositary Shares through an exercise or conversion transaction at $119.96 per ADS.
On July 20–21, 2026, he sold an aggregate 109,713 American Depositary Shares in multiple open-market or private transactions at weighted-average prices within ranges from $309.39 to $320.39 per ADS under a Rule 10b5-1 trading plan adopted on March 10, 2026. After these trades he reported 4,461,518 Ordinary Shares held directly, plus additional Ordinary Shares held indirectly through various trusts and entities, some of which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.
BeOne Medicines Ltd. director and CEO John Oyler exercised options to acquire 64,628 American Depositary Shares (ADS), representing 840,164 Ordinary Shares, at $119.96 per ADS, and then sold 64,628 ADS in multiple open-market transactions at weighted-average prices, with execution prices ranging from $304.96 to $315.18 per ADS, pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. Following these transactions, he directly holds 5,445,917 Ordinary Shares, and the filing also lists substantial indirect holdings in various trusts and Oyler Investment LLC, for which beneficial ownership is disclaimed, as well as 9,545,000 Ordinary Shares held for his benefit in a Roth IRA.
BeOne Medicines Ltd. CEO John Oyler exercised options to acquire 283,154 American Depositary Shares (ADS) and sold the same number on July 15–16, 2026 at weighted average prices from $310.0201 to $323.5858 per ADS under a Rule 10b5-1 trading plan adopted March 10, 2026.
After the trades, he reported no directly held ADS and held 5,445,917 ordinary shares directly as of July 15, 2026, plus indirect positions via trusts and an IRA, including holdings for which he disclaims beneficial ownership, and 1,282,034 share options with a $9.23 exercise price.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported both option exercises and share sales. On July 14, 2026 he exercised options covering 1,736,800 ordinary shares and sold 145,861 American Depositary Shares at prices between $302.48 and $307.87 per ADS under a Rule 10b5-1 trading plan. After these transactions he holds 5,445,917 ordinary shares directly, additional indirect interests through trusts and a Roth IRA, and 462,866 remaining share options.
BeOne Medicines Ltd. CEO John Oyler exercised options for 60,218 American Depositary Shares at $36.90 and sold 60,218 ADS in open‑market trades in July 2026 at weighted‑average prices between $295.66 and $307.44 under a Rule 10b5‑1 plan, leaving no directly held ADS. The filing also lists 5,605,310 ordinary shares held directly as of July 10, 2026 and additional ordinary shares recorded as indirectly held through various trusts and a Roth IRA, with beneficial ownership disclaimed for several trust positions.
BeOne Medicines Ltd. senior vice president and general counsel Lee Chan Henry reported option exercises and an associated sale of American Depositary Shares (ADSs). On July 8, 2026, he exercised options to acquire multiple blocks of ADSs and sold 664 ADSs at $302.46 per ADS in an open-market transaction pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he held 338,884 Ordinary Shares directly, and continued to hold several option positions over Ordinary Shares with stated exercise prices and future expiration dates.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported a small share disposal tied to tax withholding rather than a discretionary sale. On June 23, 2026, 1,292 American Depositary Shares (ADS) were sold at a weighted average price of $276.2592 per ADS under a mandatory tax withholding provision associated with the vesting of a restricted share unit award.
The restricted share units vest in four equal installments on each anniversary of June 22, 2022, subject to continued service, with potential accelerated vesting upon certain termination events. Following this transaction, Wu holds 12,365 ADS directly, 4,000 ADS indirectly through his spouse, and 1,273,724 ordinary shares directly.
BeOne Medicines Ltd. director and CEO John Oyler reported transactions involving American Depositary Shares (ADSs) tied to his equity compensation. On June 23, 2026, entities associated with him disposed of a total of 3,410 ADSs in open-market sales at weighted average prices between $272.655 and $275.21.
Each ADS represents 13 Ordinary Shares. Footnotes state these sales were effected under a mandatory tax withholding provision in his restricted share unit award agreement upon vesting, rather than as discretionary sales. Following these transactions, Oyler holds 5,605,310 Ordinary Shares directly and additional Ordinary Shares indirectly through various trusts and an LLC, while he disclaims beneficial ownership of certain trust-held securities.
BeOne Medicines Ltd. President and Global Head of R&D Wang Lai reported a small sale of 1,068 American Depositary Shares of the company. The shares were sold at $276.735 per ADS and the transaction is described as an open-market sale.
According to a footnote, this sale was carried out under a mandatory tax withholding provision tied to the vesting of a restricted share unit award that began vesting on June 22, 2022. Each ADS represents 13 ordinary shares.
After these transactions, Wang Lai holds 1,681,004 ordinary shares directly and 601,965 ordinary shares indirectly. Additional RMB Shares are held through structures such as Wang Holdings LLC and an RMB Shares Employee Participation Plan, where he has only indirect economic interest and explicitly disclaims Section 16 beneficial ownership beyond any pecuniary interest.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported an open-market sale of 1,357 American Depositary Shares (ADS) at a weighted average price of $266.7626 per ADS. The footnotes state this sale was mandated by a tax withholding provision tied to the vesting of a restricted share unit (RSU) award previously granted to him.
Each ADS represents 13 ordinary shares. Following the transaction, Wu holds 12,365 ADS directly, 4,000 ADS indirectly through his wife, and 1,290,520 ordinary shares directly, indicating he retains a substantial equity position. The RSU award vests in four equal annual installments on each anniversary of June 15, 2023, with unvested units subject to accelerated vesting upon certain termination events.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported open‑market sales of 3,693 American Depositary Shares on June 16, 2026. The ADS were sold in three trades at weighted average prices of about $264.87 to $266.69 per ADS.
According to a footnote, these sales were executed under a mandatory tax‑withholding provision tied to the vesting of a restricted share unit award previously granted to him. After these transactions, Oyler directly holds 5,649,640 Ordinary Shares and also reports several indirect Ordinary Share holdings via trusts and an LLC, for some of which he disclaims beneficial ownership.
BeOne Medicines Ltd. executive Henry Lee Chan reported an automated sale of American Depositary Shares to satisfy tax obligations tied to restricted share unit vesting. He sold 590 American Depositary Shares at $265.975 each, representing 13 ordinary shares per ADS, and now directly holds 338,884 Ordinary Shares.
BeOne Medicines Ltd. executive Wang Lai reported a small mandatory share sale tied to equity compensation. On the date shown, he sold 1,169 American Depositary Shares at a weighted average price of $265.3857 per ADS to satisfy tax withholding on a vesting restricted share unit award, rather than as a discretionary trade. Each ADS represents 13 ordinary shares. After these transactions, he continues to hold 1,694,888 ordinary shares directly, while additional ordinary shares are held indirectly through Wang Holdings LLC and an employee RMB share participation plan, for which he disclaims beneficial ownership except for any pecuniary interest.
BeOne Medicines Ltd. principal accounting officer Titus B. Ball reported a mix of compensation-related share activity and tax-driven sales. On June 11, 2026, he had 169 American Depositary Shares sold in open-market transactions, with prices around $256–$258 per ADS. A footnote explains these sales were executed under a mandatory tax withholding provision tied to the vesting of an earlier restricted share unit award, rather than discretionary selling. The same day, he received a grant of 31,213 Ordinary Shares underlying restricted share units at no purchase price, bringing his direct holdings to 99,645 Ordinary Shares. These restricted share units vest in four equal annual installments starting on June 11, 2026, with potential accelerated vesting upon certain termination events. Each ADS represents 13 Ordinary Shares, connecting the ADS activity to the underlying ordinary share structure.
BeOne Medicines Ltd. executive Wang Lai reported equity compensation grants and a small tax‑related share sale. He received 118,625 Ordinary Shares as a restricted share unit award and 229,775 share options with a $20.81 exercise price, both vesting over four years, subject to continued service and potential accelerated vesting upon certain termination events.
A total of 756 American Depositary Shares, each representing 13 Ordinary Shares, were sold at a weighted average price of about $261.00 per ADS under a mandatory tax withholding provision tied to a prior restricted share unit vesting, rather than a discretionary open‑market sale. Following these transactions, he directly holds 1,710,085 Ordinary Shares and 229,775 options, while additional Ordinary and RMB Shares are held by entities such as Wang Holdings LLC and the RMB Shares Employee Participation Plan, over which he disclaims Section 16 beneficial ownership and generally lacks voting or dispositive power.
BeOne Medicines Ltd. Chief Financial Officer Aaron Rosenberg reported routine equity compensation activity and a small tax-related sale. He sold 631 American Depositary Shares in an open-market transaction at a weighted average price of $257.7441 per ADS, executed pursuant to a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each ADS represents 13 Ordinary Shares.
Rosenberg also received 71,175 Ordinary Shares as a grant or award, bringing his direct Ordinary Share holdings to 397,891 shares. In addition, he was granted options over 137,865 Ordinary Shares with an exercise price of $20.81 per share, expiring on June 10, 2036. Both the new restricted share units and options vest over four years, with 25% vesting on the first anniversary of June 11, 2026 and the remainder vesting in equal installments thereafter, subject to continued service and potential accelerated vesting upon certain termination events.
BeOne Medicines President and COO Wu Xiaobin reported new equity awards and a small tax-related sale. He received 118,625 Ordinary Shares through a restricted share unit grant and 229,775 share options with a $20.81 exercise price, both as compensation.
He also sold 626 American Depositary Shares at a weighted average price of $261.2017 per ADS to satisfy mandatory tax withholding tied to earlier restricted share unit vesting. After these awards, he directly holds 1,308,161 Ordinary Shares and 229,775 share options, and indirectly 4,000 ADS held by his wife.
BeOne Medicines Ltd. senior vice president and general counsel Henry Lee Chan reported a mix of equity transactions. He sold 428 American Depositary Shares at $257.635 per ADS pursuant to a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each ADS represents 13 Ordinary Shares.
He also acquired 45,071 Ordinary Shares underlying restricted share units that vest over four years starting on June 11, 2026, with 1/4 vesting on each anniversary, subject to continued service. In addition, he received a share option for 87,308 Ordinary Shares at an exercise price of $20.81 per share, expiring on June 10, 2036, vesting 25% on the first anniversary of June 11, 2026 and monthly thereafter. Following these transactions, he directly holds 346,554 Ordinary Shares and 87,308 options.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported a mix of equity awards and routine share sales related to tax withholding. He received 177,931 Ordinary Shares underlying restricted share units, scheduled to vest in four equal annual installments starting on June 11, 2026, with potential accelerated vesting upon a change of control or certain termination events.
Oyler also received a share option covering 344,669 Ordinary Shares at an exercise price of $20.8100 per share, vesting over four years on a similar schedule. The filing shows open‑market sales totaling 1,949 American Depositary Shares at weighted average prices around $256–$259; these were effected under a mandatory tax withholding provision tied to a previously granted restricted share unit award. Each American Depositary Share represents 13 Ordinary Shares. Several large blocks of Ordinary Shares are held indirectly through trusts, an LLC, and a Roth IRA account, and the filing states that Oyler disclaims beneficial ownership of multiple indirect holdings.
BeOne Medicines Ltd. director and scientific advisory board chair Xiaodong Wang reported new equity awards. He received 99,892 Ordinary Shares at a price of $0.00 per share, bringing his direct holdings to 4,682,493 Ordinary Shares after the award.
Wang was also granted a share option for 193,492 Ordinary Shares with an exercise price of $20.81 per share, expiring on June 10, 2036. The footnotes state that these option shares vest over four years, with 25% vesting on the first anniversary of June 11, 2026 and the remainder in 36 monthly installments, subject to continued service. Additional Ordinary Shares are held indirectly by a family trust, Wang Investment LLC, and Wang’s spouse, for which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.
BRANDICOURT OLIVIER reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Olivier Brandicourt received a grant of 18,980 Ordinary Shares in the form of restricted share units on June 11, 2026 at no cash cost, as director compensation. These restricted share units vest in full on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Brandicourt directly holds 46,306 Ordinary Shares.
HOOPER ANTHONY C reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Anthony C. Hooper received an equity grant of 18,980 Ordinary Shares in the form of restricted share units at no cash cost on 2026-06-11. These restricted share units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Hooper holds 83,720 Ordinary Shares directly.
Mooney Elizabeth Fisher reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Elizabeth Fisher Mooney received an equity grant representing 18,980 Ordinary Shares on a Form 4 filing. These shares underlie restricted share units granted at a price of $0.00 per share as a compensation award rather than a market purchase.
The restricted share units will become fully vested on the earlier of the first anniversary of the grant date or the date of the next annual general meeting. Vesting stops if she resigns from the board or otherwise ceases to serve as a director, unless accelerated under the company’s Independent Non-Executive Director Compensation Policy.
Dugan Margaret reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Margaret Dugan received an equity award of 18,980 Ordinary Shares on June 11, 2026, reported at a price of $0.0000 per share. These represent securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting provisions under the company’s Independent Non-Executive Director Compensation Policy. Following this grant, Dugan directly holds 73,164 Ordinary Shares.
Sawyers Charles Lazelle reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Charles Lazelle Sawyers reported a grant of 18,980 Ordinary Shares as a share-based award. The award represents restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and any accelerated vesting triggers under the company’s Independent Non-Executive Director Compensation Policy. Following the award, he holds 18,984 Ordinary Shares directly. A separate entry shows 1,946 American Depositary Shares held directly, and each American Depositary Share represents 13 Ordinary Shares.
Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Shalini Sharp reported a compensation-related equity award. She received 18,980 Ordinary Shares for no cash payment, described as securities underlying restricted share units that vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service and possible accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. After this award, she directly holds 38,116 Ordinary Shares. A separate line shows direct ownership of 9 American Depositary Shares, with each American Depositary Share representing 13 Ordinary Shares.
Riva Alessandro reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. director Alessandro Riva received a grant of 18,980 ordinary shares in the form of restricted share units at no purchase price. These units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to his continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Riva directly holds 73,164 ordinary shares.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported a compensation-related equity grant linked to its board. On June 11, 2026, the company granted 18,980 restricted share units payable solely in ordinary shares to Felix J. Baker in connection with his election to the board under the 2016 Share Option and Incentive Plan. The RSUs vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to continued board service. Due to the Baker Bros. fund structure, the RSU grant and resulting ordinary shares are reflected as indirect proportionate pecuniary interests of affiliated funds, with investment adviser Baker Bros. Advisors LP holding voting and dispositive power. The filing also notes indirect and direct holdings of American Depositary Shares, with each ADS representing 13 ordinary shares.
BeOne Medicines Ltd. Principal Accounting Officer Titus B. Ball reported routine tax-related share sales. On June 8, 2026, he sold a total of 136 American Depositary Shares of BeOne Medicines in open-market transactions at weighted average prices of about $271.06 and $272.08. Footnotes state these sales were required under a mandatory tax withholding provision tied to the vesting of a previously granted restricted share unit award. Following these transactions, Ball reported direct ownership of 70,629 Ordinary Shares of BeOne Medicines.
BeOne Medicines Ltd. reported that SVP and General Counsel Henry Lee Chan disposed of American Depositary Shares mainly to satisfy tax obligations tied to vesting equity awards. On June 8, 2026, he sold a total of 871 American Depositary Shares in open-market transactions at weighted average prices around $270–$271 per ADS, pursuant to a mandatory tax withholding provision in his restricted share unit agreement.
Each American Depositary Share represents 13 Ordinary Shares. After these transactions, he continued to hold 307,047 Ordinary Shares directly, indicating he retains a substantial equity position in the company while using a portion of vested shares to cover tax requirements.
BeOne Medicines Ltd. executive Wang Lai, President and Global Head of R&D, reported selling 1,367 American Depositary Shares (ADS) on June 8, 2026 at weighted average prices around $269–$271. Each ADS represents 13 ordinary shares.
The sale was carried out under a mandatory tax withholding provision linked to the vesting of a restricted share unit award, rather than a discretionary open-market sale. Following these transactions, Wang Lai holds 1,601,288 ordinary shares directly and has additional indirect interests through entities and participation in an RMB employee share plan, with certain interests disclaimed as beneficial ownership under Section 16.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported selling 1,484 American Depositary Shares on June 8, 2026 in open-market transactions at prices of $270.55 and a weighted average of $269.3325 per ADS. According to the filing, the sale was effected under a mandatory tax withholding provision tied to the vesting of a restricted share unit award granted to him.
Following these transactions, he holds 40 American Depositary Shares directly, 4,000 American Depositary Shares indirectly through his wife, and 1,197,713 ordinary shares, which include 481 ordinary shares acquired through the company’s 2018 Employee Share Purchase Plan. Each ADS represents 13 ordinary shares.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported tax-related transactions in American Depositary Shares (ADSs). On June 8, 2026, a total of 4,940 ADSs were sold at weighted average prices of about $270–$271 per ADS. A footnote explains the sale was carried out under a mandatory tax withholding provision connected to the vesting of a previously granted restricted share unit award, rather than a discretionary open-market sale. Each ADS represents 13 Ordinary Shares. Following these transactions, Oyler held no ADSs directly, but continued to have substantial Ordinary Share holdings directly and through various trusts and entities, some of which he disclaims beneficial ownership in the footnotes.
BeOne Medicines Ltd. director Yi Qingqing reported a small share disposition linked to equity compensation. On June 1, 2026, Yi disposed of 235 American Depositary Shares of BeOne Medicines at $279.13 per ADS. According to the disclosure, this sale was carried out under a mandatory tax withholding provision in Yi’s restricted share unit (RSU) agreement in connection with RSU vesting, rather than as a discretionary open-market trade. Following the transactions reported, Yi holds 24,271 Ordinary Shares directly, reflecting a continuing equity stake in the company.
BeOne Medicines director Margaret Dugan disposed American Depositary Shares to satisfy tax withholding on vested restricted share units. She sold 212 American Depositary Shares at an average price of $309.6017 per ADS in an open-market transaction tied to a mandatory tax provision in her RSU award agreement.
Each American Depositary Share represents 13 Ordinary Shares. After these transactions, she holds 54,184 Ordinary Shares directly and no American Depositary Shares, indicating she retained a substantial equity position while covering tax obligations from the RSU vesting.
BeOne Medicines Ltd. director Sanders Corazon (Corsee) D. reported a small tax-related share sale. On May 22, 2026, the director sold 212 American Depositary Shares at $309.5896 per ADS, with each ADS representing 13 Ordinary Shares. The sale was mandated under a tax withholding provision tied to the vesting of a restricted share unit award, rather than a discretionary market trade.
Following this transaction, the director holds 54,470 Ordinary Shares directly and no American Depositary Shares. The footnotes state that the restricted share units vest based on service on the board, with potential accelerated vesting upon a change in control or certain termination events.
BeOne Medicines Ltd. insiders linked to Baker Bros. entities reported small share sales tied to RSU vesting and tax withholding. On May 22, 2026, Michael Goller sold 2,743 ordinary shares at $23.8512 per share and Ranjeev Krishana sold 2,756 ordinary shares at $23.7905 per share. Footnotes explain these 5,499 ordinary shares, in the form of 423 American Depositary Shares (ADS), were sold in connection with the vesting of restricted stock units as mandatory tax-withholding transactions, not discretionary open-market selling. The positions are attributed to funds advised by Baker Bros. Advisors LP, which has voting and dispositive power, while Julian and Felix Baker and related entities disclaim beneficial ownership beyond their indirect pecuniary interest. After these transactions, the funds continue to hold large positions, including 8,068,411 ADS and 730,642 ADS reported as indirect holdings.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised employee share options covering 4,316 Ordinary Shares at exercise prices of $12.23, $16.41, and $14.96 per share. The options were represented as Share Options (Right to Buy) and convert into Ordinary Shares.
On the same date, he sold 332 American Depositary Shares at an average price of $310.72 per ADS in an open-market transaction made under a Rule 10b5-1 trading plan. Following these transactions, he directly owns 318,370 Ordinary Shares and no American Depositary Shares.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry reported a series of routine equity transactions. He exercised options to acquire 4,433 Ordinary Shares at exercise prices of 14.96, 16.41, and 12.23 per share, which converted into 341 American Depositary Shares (ADSs). Each ADS represents 13 Ordinary Shares. He then sold 341 ADSs at 300.00 per ADS in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 318,370 Ordinary Shares, indicating he retains a substantial equity position in the company.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.